This Is MS Multiple Sclerosis Knowledge & Support Community

This article describes a Phase III trial of a new formulation of Avonex taken every two or four weeks and comments on competition with Tysabri and some of the oral meds in trial. Looks like Cladribine and Fingolimod are still on track for FDA filing this year. Novartis releases its first quarter results on April 23, so there should be an update on Fingolimod then as well.

http://www.thestreet.com/story/10477612 ... ivals.html